Knight Announces Filing of New Drug Submission for IbsrelaTM in Canada
(WorldNews Canada)

MONTREAL, June 26, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (`Knight`), a Canadian specialty pharmaceutical company, announced today that Knight`s New Drug Submission (NDS) for IbsrelaTM (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C). Knight and Ardelyx Inc. (NASDAQ: ARDX) entered into a license agreement in March 2018 granting Knight the exclusive right to commercialize tenapanor in Canada. ......